1940, the eighth route army sanitary materials factory merged with 129 normal college of pharmacy in anlezhuang, and was named as the sanitary materials factory of the 18th Army Field Health Department.
1947 summer, sanitary materials factory moved south with Liu Deng army, 1949 autumn entered Wuhan, 1957 July handed over to the local government, named Wuhan Pharmaceutical Factory.
1955, moved to Chenjiadun on the bank of Hanshui River.
1953 In July, according to the instructions of Premier Zhou, the martial arts doctors began to develop insulin, which was put into production in 1956, and its technical indicators exceeded the standards of the former Soviet Union at the same time.
From 1958 to 1960, 59 new products were successfully trial-produced and put into production 12. Among them, norepinephrine, pararenin, Anluoxue and Weifukang dimercaprol have become the only products in China. Analgin and chloramphenicol become high-quality products; Insulin and adrenocorticotropic hormone are first-class products in China.
1960, dimercaprol, norepinephrine, pararenin, sodium sulfate, furosemide and other injections were produced by Wushu doctors.
At the beginning of 1960, Wu Yao took the lead in successfully developing metronidazole, and it was officially produced in the same year 10. In 1960s, the raw materials of preparations began to be exported.
65438-0966 exported Shuweining tablets, and 65438-0969 exported metronidazole raw materials to earn foreign exchange.
Bainaiting Eye Drops developed exclusively by Wu Yao 1976 for clinical use. 1April, 977, its raw materials and preparations expanded production. Since 1978 went on the market, it has been trusted by cataract patients, with sales exceeding 300 million tablets. Won 1982 "National Silver Award".
In the late 1980s, Five Drugs successfully developed the fourth generation of quinolones-enoxacin, which became the first new second-class antibiotic drug after the implementation of the new drug approval law in China. Up to now, Nuojia series-Enoxacin raw materials and its preparation products such as infusion, small needle, powder needle, tablet, capsule and eye drops have been developed.
199 1, Wushu was approved as a national second-class enterprise, 1992, and won the "National May 1st Labor Award".
1994, Five Pharmaceuticals was restructured into Wuhan Pharmaceutical (Group) Co., Ltd., and renamed Wuhan Nuojia Pharmaceutical Group Co., Ltd. in 2000.
200 1, Wushu was rated as a high-tech enterprise in Wuhan.
In 2002, China Yuanda Group entered Wushu, and its share capital increased to 85 million yuan.
In 2004, Xinweining (tirofiban hydrochloride and sodium chloride injection), a second-class new drug successfully developed by Wushu medicine, was first listed in China. At present, it has been clinically applied in nearly 300 hospitals, treating more than 5,000 patients and becoming a protective drug for interventional therapy of acute coronary syndrome.
In 2005, Wushu won the title of "High-tech Enterprise" and "Excellent Private Enterprise in Hubei Province" in the Torch Program of the Ministry of Science and Technology.
In 2006, Wushu won the "Wuhan May 1st Labor Award".
In August 2005, Wuyao became a Sino-foreign joint venture.
In April 2007, Wuhan Yuanda Pharmaceutical Group joined hands with the International Orbis Aircraft Eye Hospital to prevent blindness.